A Phase 1b/2a study of Alintegimod with Ipilimumab and Nivolumab in cancer patients

Study Description

An early study to test the safety and effectiveness of a new drug called Alintegimod when combined with Ipilimumab and Nivolumab in cancer patients

Study Details

Registry ID:

NCT06362369

Conditions:

Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations

Phase:

Phase 1,Phase 2

Target Enrollment:

126 participants

Start Date:

August 23, 2024

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Brown University Health Cancer Institute
  Providence, Rhode IslandUnited States, United States
• Dartmouth Hitchcock
  Lebanon, New HampshireUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• University of Colorado Cancer Center
  Aurora, ColoradoUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →